Published in Infect Immun on March 01, 1992
Tularemia. Clin Microbiol Rev (2002) 8.51
An attenuated strain of the facultative intracellular bacterium Francisella tularensis can escape the phagosome of monocytic cells. Infect Immun (2003) 4.37
Early pathogenesis of infection in the liver with the facultative intracellular bacteria Listeria monocytogenes, Francisella tularensis, and Salmonella typhimurium involves lysis of infected hepatocytes by leukocytes. Infect Immun (1992) 3.52
Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect Immun (1993) 3.16
Construction and characterization of a highly efficient Francisella shuttle plasmid. Appl Environ Microbiol (2004) 2.71
Francisella tularensis: taxonomy, genetics, and Immunopathogenesis of a potential agent of biowarfare. Annu Rev Microbiol (2006) 2.68
Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection. Infect Immun (1994) 2.61
Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth. Infect Immun (1995) 2.52
Identification of proteins of Francisella tularensis induced during growth in macrophages and cloning of the gene encoding a prominently induced 23-kilodalton protein. Infect Immun (1997) 2.40
In vivo clearance of an intracellular bacterium, Francisella tularensis LVS, is dependent on the p40 subunit of interleukin-12 (IL-12) but not on IL-12 p70. Infect Immun (2002) 2.02
Murine macrophages kill the vegetative form of Bacillus anthracis. Infect Immun (2005) 1.91
Susceptibility to secondary Francisella tularensis live vaccine strain infection in B-cell-deficient mice is associated with neutrophilia but not with defects in specific T-cell-mediated immunity. Infect Immun (2001) 1.91
Detection of Francisella tularensis in blood by polymerase chain reaction. J Clin Microbiol (1993) 1.75
Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infect Immun (1994) 1.75
Endogenous interleukin-12 is involved in resistance to Brucella abortus infection. Infect Immun (1995) 1.70
Microarray analysis of human monocytes infected with Francisella tularensis identifies new targets of host response subversion. PLoS One (2008) 1.67
Respiratory Francisella tularensis live vaccine strain infection induces Th17 cells and prostaglandin E2, which inhibits generation of gamma interferon-positive T cells. Infect Immun (2008) 1.66
Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun (1993) 1.65
Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways. J Immunol (2008) 1.64
Resistance of Francisella tularensis strains against reactive nitrogen and oxygen species with special reference to the role of KatG. Infect Immun (2007) 1.64
Interleukin-12 in infectious diseases. Clin Microbiol Rev (1997) 1.63
CD4+ and CD8+ T-cell-dependent and -independent host defense mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice. Infect Immun (1994) 1.50
Multiple T cell subsets control Francisella tularensis LVS intracellular growth without stimulation through macrophage interferon gamma receptors. J Exp Med (2003) 1.45
Cytokine expression in the liver during the early phase of murine tularemia. Infect Immun (1995) 1.39
In vivo regulation of replicative Legionella pneumophila lung infection by endogenous tumor necrosis factor alpha and nitric oxide. Infect Immun (1995) 1.36
Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest (1996) 1.36
Rapid local expression of interleukin-12, tumor necrosis factor alpha, and gamma interferon after cutaneous Francisella tularensis infection in tularemia-immune mice. Infect Immun (1999) 1.36
Effects of opsonization and gamma interferon on growth of Brucella melitensis 16M in mouse peritoneal macrophages in vitro. Infect Immun (2000) 1.36
Bactericidal activities of antibiotics against intracellular Francisella tularensis. Antimicrob Agents Chemother (2000) 1.30
Endogenous interleukin-12 is involved in resistance of mice to Mycobacterium avium complex infection. Infect Immun (1995) 1.27
Inhibition of nitric oxide synthesis increases mortality in Sindbis virus encephalitis. J Virol (1996) 1.25
Restricted cytosolic growth of Francisella tularensis subsp. tularensis by IFN-gamma activation of macrophages. Microbiology (2009) 1.20
Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob Agents Chemother (2004) 1.20
Importance of nitric oxide synthase in the control of infection by Bacillus anthracis. Infect Immun (2006) 1.18
Basis for the failure of Francisella tularensis lipopolysaccharide to prime human polymorphonuclear leukocytes. Infect Immun (2006) 1.17
The involvement of IL-17A in the murine response to sub-lethal inhalational infection with Francisella tularensis. PLoS One (2010) 1.16
The francisella intracellular life cycle: toward molecular mechanisms of intracellular survival and proliferation. Front Microbiol (2010) 1.14
Cytokines and nitric oxide as effector molecules against parasitic infections. Philos Trans R Soc Lond B Biol Sci (1997) 1.13
Protective role of Bacillus anthracis exosporium in macrophage-mediated killing by nitric oxide. Infect Immun (2007) 1.12
Mechanisms of Francisella tularensis intracellular pathogenesis. Cold Spring Harb Perspect Med (2013) 1.10
Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J Immunol (2008) 1.09
Use of aminoglycosides in treatment of infections due to intracellular bacteria. Antimicrob Agents Chemother (2001) 1.07
Identification of Francisella tularensis live vaccine strain CuZn superoxide dismutase as critical for resistance to extracellularly generated reactive oxygen species. J Bacteriol (2009) 1.05
Lack of involvement of nitric oxide in killing of Aspergillus fumigatus conidia by pulmonary alveolar macrophages. Infect Immun (1995) 1.05
Generation of a convalescent model of virulent Francisella tularensis infection for assessment of host requirements for survival of tularemia. PLoS One (2012) 1.04
Francisella tularensis induces ubiquitin-dependent major histocompatibility complex class II degradation in activated macrophages. Infect Immun (2009) 1.04
Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine (2009) 1.03
Nitrite production by macrophages derived from BCG-resistant and -susceptible congenic mouse strains in response to IFN-gamma and infection with BCG. Immunology (1994) 1.02
Role of Bacillus anthracis spore structures in macrophage cytokine responses. Infect Immun (2007) 1.01
Coactivating signals for the hepatic lymphocyte gamma interferon response to Francisella tularensis. Infect Immun (2006) 1.00
New protein fold revealed by a 1.65 A resolution crystal structure of Francisella tularensis pathogenicity island protein IglC. Protein Sci (2007) 0.98
The subversion of the immune system by francisella tularensis. Front Microbiol (2011) 0.98
Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens. PLoS Pathog (2010) 0.97
Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect Immun (1995) 0.95
Heat stress alters the virulence of a rifampin-resistant mutant of Francisella tularensis LVS. Infect Immun (1995) 0.93
Type A Francisella tularensis acid phosphatases contribute to pathogenesis. PLoS One (2013) 0.92
A Francisella tularensis locus required for spermine responsiveness is necessary for virulence. Infect Immun (2011) 0.92
Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge. J Leukoc Biol (2011) 0.92
Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis. Vaccine (2009) 0.91
Vaccines against tularemia. Hum Vaccin (2009) 0.91
Influence of the bcg locus on natural resistance to primary infection with the facultative intracellular bacterium Francisella tularensis in mice. Infect Immun (2000) 0.89
Francisella inhibits STAT1-mediated signaling in macrophages and prevents activation of antigen-specific T cells. Int Immunol (2008) 0.88
Host-pathogen interactions and immune evasion strategies in Francisella tularensis pathogenicity. Infect Drug Resist (2014) 0.87
The mechanism of the inhibitory effect of polyamines on the induction of nitric oxide synthase: role of aldehyde metabolites. Br J Pharmacol (1994) 0.86
The Francisella tularensis LVS ΔpdpC mutant exhibits a unique phenotype during intracellular infection. BMC Microbiol (2013) 0.83
Roles of reactive oxygen species-degrading enzymes of Francisella tularensis SCHU S4. Infect Immun (2015) 0.82
Role of pathogenicity determinant protein C (PdpC) in determining the virulence of the Francisella tularensis subspecies tularensis SCHU. PLoS One (2014) 0.81
T lymphocytes from granulocyte colony-stimulating factor-/- mice produce large quantities of interferon-gamma in a chronic infection model. Immunology (2000) 0.81
Tularemia vaccine development: paralysis or progress? Vaccine (Auckl) (2016) 0.81
IKKβ in myeloid cells controls the host response to lethal and sublethal Francisella tularensis LVS infection. PLoS One (2013) 0.80
Francisella tularensis LVS induction of prostaglandin biosynthesis by infected macrophages requires specific host phospholipases and lipid phosphatases. Infect Immun (2014) 0.79
Interleukin-12-secreting fibroblasts are more efficient than free recombinant interleukin-12 in inducing the persistent resistance to Mycobacterium avium complex infection. Immunology (1999) 0.79
Induction of in vivo resistance to Mycobacterium avium infection by intramuscular injection with DNA encoding interleukin-18. Immunology (2001) 0.79
Establishment of three Francisella infections in zebrafish embryos at different temperatures. Infect Immun (2014) 0.78
Phenotypic, morphological, and functional heterogeneity of splenic immature myeloid cells in the host response to tularemia. Infect Immun (2012) 0.78
Cytokine response in Balb/c mice infected with Francisella tularensis LVS and the Pohang isolate. J Vet Sci (2008) 0.77
Control of intracellular Francisella tularensis by different cell types and the role of nitric oxide. J Immunol Res (2014) 0.77
A Protective Role for Macrophages in Respiratory Francisella tularensis Infection. Infect Immun (2017) 0.76
Tryptophan prototrophy contributes to Francisella tularensis evasion of gamma interferon-mediated host defense. Infect Immun (2011) 0.76
Inhibitors of Ribosome Rescue Arrest Growth of Francisella tularensis at All Stages of Intracellular Replication. Antimicrob Agents Chemother (2016) 0.75
Identification of Genes Required for Secretion of the Francisella Oxidative Burst-Inhibiting Acid Phosphatase AcpA. Front Microbiol (2016) 0.75
Endotoxin-induced tumor necrosis factor alpha synthesis in murine embryo fibroblasts. Infect Immun (1993) 0.75
Control of Francisella tularensis Intracellular Growth by Pulmonary Epithelial Cells. PLoS One (2015) 0.75
Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity. Clin Vaccine Immunol (2017) 0.75
Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem (1982) 27.26
Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes. J Cell Biol (1989) 15.41
Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med (1971) 11.44
The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell (1989) 10.98
The interaction between Toxoplasma gondii and mammalian cells. II. The absence of lysosomal fusion with phagocytic vacuoles containing living parasites. J Exp Med (1972) 8.66
Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol (1961) 7.52
Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci U S A (1985) 7.15
Activation of mononuclear phagocytes: fact, fancy, and future. J Immunol (1978) 6.22
Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell Immunol (1991) 5.41
Nature of protective immunity to Francisella tularensis. Rev Infect Dis (1989) 4.75
Microbiostatic effect of murine-activated macrophages for Toxoplasma gondii. Role for synthesis of inorganic nitrogen oxides from L-arginine. J Immunol (1990) 4.62
Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol (1990) 4.36
Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun (1991) 3.99
Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol (1989) 3.90
Growth of Francisella spp. in rodent macrophages. Infect Immun (1991) 3.81
Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J Immunol (1990) 3.79
Multiplication of a human parasite (Leishmania donovani) in phagolysosomes of hamster macrophages in vitro. Science (1976) 3.55
Interferon gamma-activated human monocytes downregulate transferrin receptors and inhibit the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. J Clin Invest (1989) 3.36
Experimental infection of mouse peritoneal mesothelium with scrub typhus rickettsiae: an ultrastructural study. Infect Immun (1978) 3.26
Macrophage cytotoxicity against schistosomula of Schistosoma mansoni involves arginine-dependent production of reactive nitrogen intermediates. J Immunol (1989) 3.09
Killing of Listeria monocytogenes by inflammatory neutrophils and mononuclear phagocytes from immune and nonimmune mice. J Leukoc Biol (1984) 3.02
Macrophage microbicidal activity. Correlation between phagocytosis-associated oxidative metabolism and the killing of Candida by macrophages. J Exp Med (1980) 2.96
Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J Clin Invest (1990) 2.91
The requirement for gamma interferon in resistance of mice to experimental tularemia. Microb Pathog (1989) 2.35
Cytokine-induced synthesis of nitrogen oxides in macrophages: a protective host response to Leishmania and other intracellular pathogens. J Leukoc Biol (1991) 2.30
Antimicrobial susceptibility testing of Francisella tularensis with a modified Mueller-Hinton broth. J Clin Microbiol (1985) 2.26
Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect Immun (1989) 2.25
Soviet viable Pasteurella tularensis vaccines. A review of selected articles. Bacteriol Rev (1962) 2.19
Genetic linkage of resistance to Listeria monocytogenes with macrophage inflammatory responses. J Immunol (1981) 2.17
Experimental murine tularemia caused by Francisella tularensis, live vaccine strain: a model of acquired cellular resistance. Microb Pathog (1987) 2.13
Rickettsial interactions with human endothelial cells in vitro: adherence and entry. Infect Immun (1984) 2.02
Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J Interferon Res (1989) 1.74
PHAGOCYTOSIS AND INTRACELLULAR FATE OF PASTEURELLA TULARENSIS. 3. IN VIVO STUDIES WITH PASSIVELY TRANSFERRED CELLS AND SERA. J Immunol (1965) 1.63
Macrophage activation to kill Leishmania tropica: defective intracellular killing of amastigotes by macrophages elicited with sterile inflammatory agents. J Immunol (1984) 1.54
A wild and an attenuated strain of Francisella tularensis differ in susceptibility to hypochlorous acid: a possible explanation of their different handling by polymorphonuclear leukocytes. Infect Immun (1984) 1.53
Murine model for study of cell-mediated immunity: protection against death from fully virulent Francisella tularensis infection. Infect Immun (1975) 1.37
Intracellular replication of Leishmania tropica in mouse peritoneal macrophages: amastigote infection of resident cells and inflammatory exudate macrophages. Infect Immun (1982) 1.26
Activation of macrophages to kill rickettsiae and Leishmania: dissociation of intracellular microbicidal activities and extracellular destruction of neoplastic and helminth targets. Contemp Top Immunobiol (1984) 1.20
The interaction of macrophages and bacteria: a comparative study of the induction of tumoricidal activity and of reactive nitrogen intermediates. Cell Immunol (1991) 1.06
Macrophages in resistance to rickettsial infections: protection against lethal Rickettsia tsutsugamushi infections by treatment of mice with macrophage-activating agents. J Leukoc Biol (1984) 0.98
A study of the sensitivity of Leishmania donovani promastigotes and amastigotes to hydrogen peroxide. II. Possible mechanisms involved in protective H2O2 scavenging. Parasitology (1985) 0.98
Mycobacterium bovis BCG-induced protection against cutaneous and systemic Leishmania major infections of mice. Infect Immun (1987) 0.87
Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science (1994) 4.50
Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J Immunol (1989) 4.44
Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol (1990) 4.36
Field trials of the Baby Check score card: mothers scoring their babies at home. Arch Dis Child (1991) 4.31
Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun (1991) 3.99
Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J Immunol (1990) 3.79
In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies. Infect Immun (1992) 3.07
Regulation of activated macrophage antimicrobial activities. Identification of lymphokines that cooperate with IFN-gamma for induction of resistance to infection. J Immunol (1988) 2.82
Field trials of the Baby Check score card in hospital. Arch Dis Child (1991) 2.64
Diversity of sulfate-reducing bacteria in oxic and anoxic regions of a microbial mat characterized by comparative analysis of dissimilatory sulfite reductase genes. Appl Environ Microbiol (1999) 2.55
Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth. Infect Immun (1995) 2.52
Intracellular replication and lymphokine-induced destruction of Leishmania tropica in C3H/HeN mouse macrophages. J Immunol (1981) 2.39
Field trials of the Baby Check score card in general practice. Arch Dis Child (1991) 2.39
Macrophages in resistance to rickettsial infection: macrophage activation in vitro for killing of Rickettsia tsutsugamushi. J Immunol (1979) 2.34
Cytokine-induced synthesis of nitrogen oxides in macrophages: a protective host response to Leishmania and other intracellular pathogens. J Leukoc Biol (1991) 2.30
Macrophages in resistance to rickettsial infections: characterization of lymphokines that induce rickettsiacidal activity in macrophages. J Immunol (1981) 1.94
Deletion of purE attenuates Brucella melitensis infection in mice. Infect Immun (1996) 1.88
Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells. J Exp Med (1994) 1.83
Host defenses in experimental scrub typhus: role of normal and activated macrophages. Infect Immun (1979) 1.76
Detection of Francisella tularensis in blood by polymerase chain reaction. J Clin Microbiol (1993) 1.75
Unexpected population distribution in a microbial mat community: sulfate-reducing bacteria localized to the highly oxic chemocline in contrast to a eukaryotic preference for anoxia. Appl Environ Microbiol (1999) 1.75
Life and death of an intracellular pathogen: Francisella tularensis and the macrophage. Immunol Ser (1994) 1.73
IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. J Immunol (1991) 1.73
Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor-beta 1. J Immunol (1991) 1.71
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med (1981) 1.70
Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun (1993) 1.65
T-cell-independent resistance to infection and generation of immunity to Francisella tularensis. Infect Immun (1993) 1.62
Introduction of Francisella tularensis at skin sites induces resistance to infection and generation of protective immunity. Microb Pathog (1992) 1.56
Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens. Immunol Lett (1994) 1.54
Macrophage activation to kill Leishmania tropica: defective intracellular killing of amastigotes by macrophages elicited with sterile inflammatory agents. J Immunol (1984) 1.54
Recognition of E-cadherin on epithelial cells by the mucosal T cell integrin alpha M290 beta 7 (alpha E beta 7). Eur J Immunol (1995) 1.47
Policies for study monitoring and interim reporting of results. J Clin Oncol (1987) 1.41
Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. Immunol Lett (1990) 1.36
Activation of macrophages for microbicidal and tumoricidal effector functions by soluble factors from EL-4, a continuous T cell line. Infect Immun (1983) 1.35
Macrophage activation for tumor cytotoxicity: analysis of intermediary reactions. J Reticuloendothel Soc (1979) 1.31
The significance of anti-S sensitization in pregnancy. Clin Lab Haematol (1990) 1.30
Susceptibility of inbred mice to Leishmania tropica infection: correlation of susceptibility with in vitro defective macrophage microbicidal activities. Cell Immunol (1983) 1.29
2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev (2000) 1.28
Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine. Am J Med Sci (1994) 1.27
Intracellular replication of Leishmania tropica in mouse peritoneal macrophages: amastigote infection of resident cells and inflammatory exudate macrophages. Infect Immun (1982) 1.26
The hyaluronate receptor is identical to a glycoprotein of Mr 85,000 (gp85) as shown by a monoclonal antibody that interferes with binding activity. J Biol Chem (1987) 1.24
Activation of macrophages to kill rickettsiae and Leishmania: dissociation of intracellular microbicidal activities and extracellular destruction of neoplastic and helminth targets. Contemp Top Immunobiol (1984) 1.20
A lymphokine distinct from interferon-gamma that activates human monocytes to kill Leishmania donovani in vitro. J Immunol (1986) 1.20
Human monocyte activation for cytotoxicity against intracellular Leishmania donovani amastigotes: induction of microbicidal activity by interferon-gamma. Cell Immunol (1985) 1.16
Biogeochemical cycling and microbial diversity in the thrombolitic microbialites of Highborne Cay, Bahamas. Geobiology (2010) 1.15
Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol (1986) 1.15
Rapid generation of specific protective immunity to Francisella tularensis. Infect Immun (1992) 1.12
Co-localization of inducible-nitric oxide synthase and Plasmodium berghei in hepatocytes from rats immunized with irradiated sporozoites. J Immunol (1995) 1.12
Macrophages in resistance to rickettsial infections: early host defense mechanisms in experimental scrub typhus. Infect Immun (1981) 1.11
Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem (2001) 1.07
Intracellular replication of Leishmania tropica in mouse peritoneal macrophages: comparison of amastigote replication in adherent and nonadherent macrophages. Infect Immun (1981) 1.06
Studies on transcriptional regulation of the mucosal T-cell integrin alphaEbeta7 (CD103). Immunology (2001) 1.06
Colony-stimulating factors and regulation of macrophage tumoricidal and microbicidal activities. Cell Immunol (1983) 1.05
Identification of a binding site for integrin alphaEbeta7 in the N-terminal domain of E-cadherin. J Biol Chem (1996) 1.05
Considerations for monitoring and evaluating treatment effects in clinical trials. Control Clin Trials (1984) 1.05
Interactions of Plasmodium berghei sporozoites and murine Kupffer cells in vitro. J Immunol (1989) 1.04
A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res (1997) 1.04
Hormonal modulation of sex differences in resistance to Leishmania major systemic infections. Infect Immun (1988) 1.03
Genetic control of systemic Leishmania major infection: identification of subline differences for susceptibility to disease. Curr Top Microbiol Immunol (1985) 1.03
IL-2. A cofactor for induction of activated macrophage resistance to infection. J Immunol (1990) 1.01
Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages. Infect Immun (1992) 1.01
Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity. J Med Chem (1998) 1.00
Regulation of activated macrophage antimicrobial activities. Cooperation of lymphokines for induction of resistance to infection. J Immunol (1988) 0.99
Macrophages in resistance to rickettsial infections: protection against lethal Rickettsia tsutsugamushi infections by treatment of mice with macrophage-activating agents. J Leukoc Biol (1984) 0.98
Detection of active tuberculosis by an MPB-64 transdermal patch: a field study. Scand J Infect Dis (2001) 0.98
Macrophages in resistance to rickettsial infection: susceptibility to lethal effects of Rickettsia akari infection in mouse strains with defective macrophage function. Cell Immunol (1980) 0.98
Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol (1986) 0.97
Killing of Leishmania tropica amastigotes by factors in normal human serum. J Immunol (1984) 0.97
Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma. Cancer (1982) 0.96
Phase II study of tamoxifen in patients with disseminated malignant melanoma. Cancer Treat Rep (1980) 0.96
Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res (2001) 0.96
Immunotherapy of tularemia: characterization of a monoclonal antibody reactive with Francisella tularensis. J Leukoc Biol (1993) 0.95
Tumor necrosis factor-alpha: central regulatory cytokine in the induction of macrophage antimicrobial activities. Pathobiology (1991) 0.95
Cytokines that regulate macrophage production of nitrogen oxides and expression of antileishmanial activities. Res Immunol (1991) 0.95
Generation of nitric oxide and clearance of interferon-gamma after BCG infection are impaired in mice that lack the interferon-gamma receptor. J Inflamm (1997) 0.94
Induction of activated macrophages in C3H/HeJ mice by avirulent Salmonella. J Immunol (1988) 0.91
Performing serial testing of treatment effects. Experientia Suppl (1982) 0.90
Macrophage activation to kill Leishmania tropica: kinetics of macrophage response to lymphokines that induce antimicrobial activities against amastigotes. J Immunol (1984) 0.90
Susceptibility of inbred mice to Leishmania tropica infection: genetic control of the development of cutaneous lesions in P/J mice. J Immunol (1984) 0.90
Cytotoxic activity and production of toxic nitrogen oxides by macrophages treated with IFN-gamma and monoclonal antibodies against the 73-kDa lipopolysaccharide receptor. J Immunol (1992) 0.89
Macrophage activation to kill Leishmania tropica: characterization of P/J mouse macrophage defects for lymphokine-induced antimicrobial activities against Leishmania tropica amastigotes. J Immunol (1984) 0.89
Phase II study of high-dose megestrol acetate in patients with advanced malignant melanoma. Cancer Treat Rep (1982) 0.88
Similar molecular requirements for antigen receptor-triggered secretion of interferon and granule enzymes by cytolytic T lymphocytes. Cell Immunol (1989) 0.87
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol (1997) 0.87
Mycobacterium bovis BCG-induced protection against cutaneous and systemic Leishmania major infections of mice. Infect Immun (1987) 0.87
Intracellular destruction of Leishmania donovani and Leishmania tropica amastigotes by activated macrophages: dissociation of these microbicidal effector activities in vitro. J Immunol (1984) 0.87
A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol (1984) 0.86
Analysis of macrophage interactions with cryopreserved amastigotes of Leishmania tropica. Infect Immun (1983) 0.86
Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma. J Clin Oncol (1985) 0.85
Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Endocrinology (2003) 0.84
Genetic control of systemic Leishmania major infections: dissociation of intrahepatic amastigote replication from control by the Lsh gene. Infect Immun (1985) 0.84
IFN-gamma produced in vivo during the first two days is critical for resolution of murine Leishmania major infections. Microb Pathog (1993) 0.83
A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer. J Clin Oncol (1984) 0.82